Respiratory syncytial virus pneumonia: Mechanisms of inflammation and prolonged airway hyperresponsiveness

Current Opinion in Infectious Diseases

Volumn 18, Issue 3, 2005, Pages 199-204

  Mejías, Asunción ^a   Chávez Bueno, Susana ^a   Ramilo, Octavio ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Asthma; Children; Respiratory syncytial virus; Wheezing

Indexed keywords

VIRUS RNA;

ASTHMA; BRONCHIOLITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; GENETIC MARKER; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PATHOGENESIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TH1 CELL; TH2 CELL; VIRUS PNEUMONIA; VIRUS REPLICATION; WHEEZING;

EID: 20044369358     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000168378.07110.72     Document Type: Review

References (48)

1. Heidema J, Kimpen JLL, van Bleek GM. Pathogenesis of respiratory syncytial virus bronchiolitis: immunology and genetics. In: Kimpen JLL, Ramilo O, editors. The microbe-host interface in respiratory tract infections. Wymondham: UK: Horizon Bioscience; 2005. pp. 233-253. Very interesting chapter that reviews the immunology and genetic factors related to RSV pathogenesis. Nicely dissects the mechanisms of RSV-induced disease in humans and animal models and the role of the innate and the adaptive immune response.
2. Spann KM, Tran KC, Chi B, et al. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol 2004; 78:4363-4369.
3. Johnson TR, Varga SM, Braciale TJ, et al. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol 2004; 78:8753-8760.
4. Devincenzo JP. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res 2004; 56:914-917.
5. Paramore LC, Ciuryla V, Ciesla G, et al. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22:275-284.
6. Respiratory syncytial virus activity: United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2004; 53:1159-1160.
7. Durbin JE, Durbin RK. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol 2004; 17:370-380.
8. Psarras S, Papadopoulos NG, Johnston SL. Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezing. Paediatr Respir Rev 2004; 5(Suppl A):S179-S184.
9. Peebles RS Jr. Viral infections, atopy, and asthma: is there a causal relationship? J Allergy Clin Immunol 2004; 113:315-318. A comprehensive review that addresses the role of RSV in the development of airway reactivity and atopy later in life.
10. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171:137-141. Excellent prospective case-control study that demonstrates the relationship between RSV LRTI early in infancy (91% of study participants were ≤6 months old) and the development of asthma or recurrent wheezing and atopy until 13 years of age.
11. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354:541-545.
12. Korppi M, Piippo-Savolainen E, Korhonen K, et al. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol 2004; 38:155-160.
13. Jafri HS, Chavez-Bueno S, Mejias A, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004; 189:1856-1865. This study shows that, in the animal model, RSV alone, without allergic presensitization, not only induced severe RSV disease but also was capable of inducing long-term AHR that correlated with the lung abnormalities observed.
14. Goetghebuer T, Isles K, Moore C, et al. Genetic predisposition to wheeze following respiratory syncytial virus bronchiolitis. Clin Exp Allergy 2004; 34:801-803.
15. Lemanske RF. Viral infections and asthma inception. J Allergy Clin Immunol 2004; 114:1023-1026. This paper outlines the role of genetic predisposition in the development of RSV-induced asthma.
16. Tal G, Mandelberg A, Dalai I, et al. Association between common toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004; 189:2057-2063.
17. Hull J, Rowlands K, Lockhart E, et al. Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. J Infect Dis 2003; 188:904-907.
18. Hoebee B, Bont L, Rietveld E, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis 2004; 189:239-247.
19. Lahti M, Lofgren J, Marttila R, et al. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res 2002; 51:696-699.
20. Hoffjan S, Ostrovnaja I, Nicolae D, et al. Genetic variation in immunoregulatory pathways and atopic phenotypes in infancy. J Allergy Clin Immunol 2004; 113:511-518.
21. Valosky J, Hishiki H, Zaoutis TE, et al. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Clin Diagn Lab Immunol 2005; 12:171-179.
22. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004; 190:373-378.
23. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004; 5(Suppl A):S119-S126. Excellent and comprehensive review of the immunopathogenesis and the different risk factors associated with RSV-induced disease.
24. Guerrero-Plata A, Ortega E, Ortiz-Navarrete V, et al. Antigen presentation by a macrophage-like cell line persistently infected with respiratory syncytial virus. Virus Res 2004; 99:95-100.
25. Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 2004; 189:1419-1430.
26. LeVine AM, Elliott J, Whitsett JA, et al. Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol 2004; 31:193-199.
27. Krishnan S, Halonen M, Welliver RC. Innate immune responses in respiratory syncytial virus infections. Viral Immunol 2004; 17:220-233. This review outlines the important role of the innate immunity (chemokines, cytokines, TLR-4, surfactant proteins) in the pathogenesis of RSV infection.
28. Matthews SP, Tregoning JS, Coyle AJ, et al. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol 2005; 79:2050-2057.
29. Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol 2004; 17:165-181. A thorough and extensive review that summarizes new aspects and current persective on RSV pathogenesis.
30. Sznajer Y, Westcott JY, Wenzel SE, et al. Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis. J Pediatr 2004; 145:115-118. Interesting case-control study that found elevated concentrations of leukotrienes (LTA4/B4) in tracheal aspirates of intubated patients with severe RSV bronchiolitis.
31. Stark JM, Khan AM, Chiappetta CL, et al. Immune and functional role of nitric oxide in a mouse model of respiratory syncytial virus infection. J Infect Dis 2005; 191:387-395. Highlights the role of nitric oxide in lung inflammation, viral replication and AHR after RSV infection, suggesting that the mechanisms of lung inflammation are independent of viral replication.
32. Juntti H, Kokkonen J, Dunder T, et al. Serum concentrations of interferon-gamma and intercellular adhesion molecule-1 eight years after an early respiratory syncytial virus infection. Clin Exp Allergy 2005; 35:59-63. Case-control study with 51 patients in each arm, evaluating the relationship between serum concentrations of IFN-γ and slCAM with atopy and wheezing 8 years after the first episode of RSV bronchiolitis.
33. Gill MA, Palucka KA, Barton T, et al. Mobilization of plasmacytoid and myeloid dendritic cells to mucosa sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis 2005; 191:1105-1115.
34. Silvestri M, Sabatini F, Defilippi AC, et al. The wheezy infant: immunological and molecular considerations. Paediatr Respir Rev 2004; 5(Suppl A):S81-S87.
35. McNamara PS, Flanagan BF, Selby AM, et al. Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. Eur Respir J 2004; 23:106-112.
36. Rutigliano JA, Graham BS. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol 2004; 173:3408-3417.
37. Roe MF, Bloxham DM, White DK, et al. Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. Clin Exp Immunol 2004; 137:139-145.
38. Rayyan M, Naulaers G, Daniels H, et al. Characteristics of respiratory syncytial virus-related apnoea in three infants. Acta Paediatr 2004; 93:847-849.
39. Openshaw PJ, Yamaguchi Y, Tregoning JS. Childhood infections, the developing immune system, and the origins of asthma. J Allergy Clin Immunol 2004; 114:1275-1277. Nice and concise review of studies in humans and animal models that highlights the impact of RSV infection in the immature immune system and its relation with the development of asthma.
40. Chávez-Bueno S, Mejías A, Olsen K, et al. Respiratory syncytial virus (RSV)-induced long-term airway hyperresponsiveness (AHR) is associated with viral persistence detected by real time polymerase chain reaction (RLT-PCR). Pediatric Academic Societies Annual Meeting; San Francisco, CA; 2004. Abstract 1908.
41. Schwarze J, O'Donnell DR, Rohwedder A, et al. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med 2004; 169:801-805. Outstanding paper showing that RSV RNA was detected in lungs from infected mice 3 months after inoculation, and that replicating virus was recovered when mice were depleted of T cells. Suggests a potential role of persistent RSV in the development of RSV-induced AHR.
42. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618-1623.
43. Cubie HA, Duncan LA, Marshall LA, et al. Detection of respiratory syncytial virus nucleic acid in archival postmortem tissue from infants. Pediatr Pathol Lab Med 1997; 17:927-938.
44. Tripp RA. The brume surrounding respiratory syncytial virus persistence [editorial]. Am J Respir Crit Care Med 2004; 169:778-779. Nice editorial that highlights the possible mechanisms related to RSV persistence.
45. Mejias A, Chavez-Bueno S, Rios AM, et al. Asthma and respiratory syncytial virus: new opportunities for therapeutic intervention. Ann Pediatr (Barc) 2004; 61:252-260.
46. Simoes EA, Carbonell-Estrany X, Kimpen J, et al. Palivizumab use decrease risk of recurrent wheezing in preterm children. In: 14th European Respiratory Society Annual Congress; Glasgow; 4-8 September 2004. Abstract 1349.
47. Mejias A, Chavez-Bueno S, Rios AM, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004; 48:1811-1822. This study emphasizes the importance of an intervention strategy in RSV disease in the mouse model. The study shows that palivizumab, especially when given before the infection, was associated with improvement of the clinical and inflammatory markers of RSV disease, including long-term AHR and lung inflammation.
48. Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50-55. Very provocative study in which the use of novel siRNA given intranasally before and after RSV infection was able to prevent and inhibit RSV infection in a time-dependent manner. This new agent opens up the possibility for new therapeutic interventions against RSV.